Recommendation of the President – Dezacor (deflazacort)
On 30 December 2024, the President of the Agency for Health Technology Assessment and Tariff System issued recommendation No. 163/2024 on the appropriateness of issuing reimbursement approvals for the medicinal product Dezacor (deflazacort) for the indication Duchenne muscular dystrophy in the pediatric patient population